Nobel BiocareInterim Report 3, 2007

Domenico ScalaCEO

2

Disclaimer

This presentation contains forward-looking statements that are subject to various risks and

uncertainties. Future results could differ materially from those described in these forward-

looking statements due to certain factors, e.g. changes in business, economic and

competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate

fluctuations, uncertainties in litigation or investigative proceedings, and the availability of

financing.

3

Continued strong revenue growth after nine months

• Revenue up 18% (l.c.) to EUR 485.0 million

• Gross margin maintained at high level: 84.3%

• Profit from operations (EBIT) up 10% - margin at 32.2%

• Profit for the period* up 12% to EUR 121.1 million

• Basic earnings per share* up 14% to EUR 4.88

• Procera® manufacturing started in Japan

• Additional CHF ~350 million cash return in 2007 through share repurchase via put option

• Outlook: 17% revenue growth, EBIT margin 33%

* Excluding sale of associate

4

Sustained revenue growth in all regions

North AmericaEUR 165.8 m11% growth (9m, in lc)34% of total revenue (9m 2007)

• Growth regaining momentum• Improving performance in

specialist segment

EuropeEUR 218.6 m17.5% growth (9m, in lc)45% of total revenue (9m 2007)

• High growth in most countries• Specific country issues addressed

Asia PacificEUR 72.4 m31.8% growth (9m, in lc)15% of total revenue (9m 2007)

• Strongest growth potential• New Procera® production

in Japan

Rest of the worldEUR 28.2 EUR m25.4% growth (9m, in lc)6% of total revenue (9m 2007)

5

Best in class financial performance

9m 2007 EUR 9m 2006 EUR Growth• Revenues 485.0 429.0 +17.5%*• Gross profit 408.9 359.3 +13.8%• Gross margin 84.3% 83.8% +50bps• EBIT 156.1 142.0 +9.9%• EBIT margin 32.2% 33.1% -90bps• EBIT margin at CER 33.2% - -• Profit for the period** 121.1 107.8 +12.3%• Basic earnings p. share 4.88 4.45 +9.7%

*Revenue growth in local currencies** Excl sale of associate

6

At CER EBIT margin at prior year level

*Revenue growth in local currencies** Excl sale of associate

ReportedEBIT

margin9M 06

33.1%+1.0%

Grossmargin

Operating expenses

0.2%

EBITmarginH1 07

32.2%

ReportedEBIT

margin9M 07

33.0%

Socialcharges

- 1.1% -1.0%

FX impact

7

Continued shareholder orientation

• Repurchase at a premium over spot price

• Equal treatment of shareholders• Granting and sale of put option

with no WHT• Commitment rather than a

statement of intent

Additional cash return in 2007 via put option

Confidence in business model and financial strength

8

Total cash return in 2007

Dividend Share buyback Put option Share buyback

EUR 2.70 per share+21%

479 150 shares

AmountEUR 224 m (CHF 350 m)

AmountEUR 64 m

AmountEUR 115 m

Total cash return 2007: EUR 403 m

~ 900 000 shares~ 25% premiumExercise date:29 November

Approx. CHF 2.50 per shareConversion ratio 28:13 weeks maturity

9

Q3 product launches on track

• Company in process of introducing ~ 300 new articles

• Most important launch is Nobel Active™: Pre-launch approach– New geometry and TiUnite® surface enable expansion of indications– 1-year prospective multi-center clinical data available– Pre-launch allows controlled introduction– Initially, only experienced users targeted– Attendance of training courses mandatory– Pre-launch will continue until further notice– Positive feedback received so far

• Procera® software introduction– Completely new platform– Enhanced features and benefits

10

Size of industryUSD billion

0

Cardiovascular

0 20 40

Orthopaedics

Adv. Wound

Hearing Aids

Endoscopy

Prem. Tooth

Replac.Prem. Tooth Replac.

20062010E Growth

Mature

Source: Deutsche Bank

3-5 years growth %

Most attractive segment in healthcare

• Best sector today and tomorrow

• Unaffected by health care reforms

• Attractive profession

• New products/solutions an essential factor10

20

11

Leading in key growth segments

EquipmentEst. annual

growth ~12%

ConsumablesEst. annualgrowth ~ 5%

PFMCAGR ~0.2%

Individualized Products (All-ceramic CAD/CAM

C&B, Laminates)CAGR ~40%*

StandardizedProducts (Implants, abutments)CAGR ~16%**

PharmaceuticalsEst. annualgrowth ~5%

*2005-2009 **2007-2011 Source: MRG, Nobel Biocare estimates, competitor information

Digitalisation

Conversion

Total dental market size~17.5bn USD (2006) ~ 3.5bn USD (2006)

Nobel Biocare served market

12

Laboratory

Restorative

Surgical

Crown & Bridge

CAD/CAMIndividualprosthetics

Guidedsurgery

Tissue Regeneration

Biologics

Implants,Standardized Prosthetics

Providing integrated root-to-tooth solutions

• Unmatched breadth of offering

• Evolving market

• Uniquely positioned through solution concepts for each segment

• Procera® with untapped potential

Procera®

13

Evolving markets require specific approach

GeneralPractitioners

Specialists

PeriodontistsEndodontists

Implantologists

DentalLaboratories

Denturists

Patients

ClinicalChains

TotalSolutionProvider

14

Take aways

• Most attractive segment in health care

• Increasing implant penetration is outpaced by demographic development

• Market leader, consistently outperforming

• Individualized products: substantial upside potential

• Leading in patents and scientific evidence

• Continued shareholder orientation

15

Financial reporting calendar

• Full Year Report 2007 11 February 2008

• Annual General Meeting 2008 27 March 2008

• Interim Report 1, 2008 30 April 2008

• Interim Report 2, 2008 11 August 2008

• Interim Report 3, 2008 03 November 2008

16

Investor contact

Suha DemokanHead of Investor RelationsTel +41 43 211 42 30,

Mobile +41 79 430 81 46

e-mail: suha.demokan@nobelbiocare.com

Gunilla EkholtzInvestor Relations OfficerTel +46 31 81 88 86

e-mail: gunilla.ekholtz@nobelbiocare.com

17